Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
September 30, 2022 07:55 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
September 21, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program,...
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
September 20, 2022 12:45 ET
|
Intercept Pharmaceuticals, Inc.
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to...
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
September 07, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
August 29, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
August 19, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
August 18, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 03, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® non-GAAP adjusted net sales in PBC of $100.4 million; U.S. net sales of $71.8 million representing 5% growth over the prior year quarter Company reissues...
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
July 27, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
July 07, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p<0.0001), consistent with the original REGENERATE analysis OCA 25...